Insulin Glargine vs Nivolumab
Insulin Glargine vs Nivolumab: Overview
This comparison examines the pharmacological differences between Insulin Glargine and Nivolumab.
Mechanism of Action
Insulin Glargine: Long-acting insulin analogue that binds insulin receptors.
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Insulin Glargine β 12-24 hours; Nivolumab β 27 days.
Chemical Properties
Type: Insulin Glargine β Protein; Nivolumab β Antibody.